Vito Alessandro Lasorsa

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/6966212/vito-alessandro-lasorsa-publications-by-year.pdf

Version: 2024-04-17

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

26 286 9 16 g-index

31 475 5.6 avg, IF L-index

#	Paper	IF	Citations
26	FGFR1 is a potential therapeutic target in neuroblastoma Cancer Cell International, 2022, 22, 174	6.4	1
25	Common variants at 21q22.3 locus influence and gene expression and susceptibility to severe COVID-19. <i>IScience</i> , 2021 , 24, 102322	6.1	21
24	Estimating asymptomatic SARS-CoV-2 infections in a geographic area of low disease incidence. <i>BMC Infectious Diseases</i> , 2021 , 21, 350	4	1
23	Regulatory Noncoding and Predicted Pathogenic Coding Variants of Predispose to Severe COVID-19. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	1
22	The H159Y Variant Is Associated with Severe COVID-19: A Retrospective Study of 500 Patients from Southern Italy. <i>Genes</i> , 2021 , 12,	4.2	1
21	miR-622 is a novel potential biomarker of breast carcinoma and impairs motility of breast cancer cells through targeting NUAK1 kinase. <i>British Journal of Cancer</i> , 2020 , 123, 426-437	8.7	10
20	Functional characterization of full-length BARD1 strengthens its role as a tumor suppressor in neuroblastoma. <i>Journal of Cancer</i> , 2020 , 11, 1495-1504	4.5	7
19	Association of PARP1 polymorphisms with response to chemotherapy in patients with high-risk neuroblastoma. <i>Journal of Cellular and Molecular Medicine</i> , 2020 , 24, 4072-4081	5.6	8
18	Kinome multigenic panel identified novel druggable EPHB4-V871I somatic variant in high-risk neuroblastoma. <i>Journal of Cellular and Molecular Medicine</i> , 2020 , 24, 6459-6471	5.6	4
17	A Targeted Gene Panel for Circulating Tumor DNA Sequencing in Neuroblastoma. <i>Frontiers in Oncology</i> , 2020 , 10, 596191	5.3	8
16	Genomic coamplification of CDK4/MDM2/FRS2 is associated with very poor prognosis and atypical clinical features in neuroblastoma patients. <i>Genes Chromosomes and Cancer</i> , 2020 , 59, 277-285	5	8
15	19p loss is significantly enriched in older age neuroblastoma patients and correlates with poor prognosis. <i>Npj Genomic Medicine</i> , 2020 , 5, 18	6.2	4
14	Gene Expression Signature of Acquired Chemoresistance in Neuroblastoma Cells. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	2
13	Genetic Analysis of the Coronavirus SARS-CoV-2 Host Protease in Different Populations. <i>Frontiers in Genetics</i> , 2020 , 11, 872	4.5	22
12	Discovery of -Enprioline as a Novel Drug for the Treatment of Vincristine Resistant Neuroblastoma. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	2
11	Neural crest-derived tumor neuroblastoma and melanoma share 1p13.2 as susceptibility locus that shows a long-range interaction with the SLC16A1 gene. <i>Carcinogenesis</i> , 2020 , 41, 284-295	4.6	11
10	Transcription Factors Involved in Tumorigenesis Are Over-Represented in Mutated Active DNA-Binding Sites in Neuroblastoma. <i>Cancer Research</i> , 2020 , 80, 382-393	10.1	7

LIST OF PUBLICATIONS

9	Exploring Shared Susceptibility between Two Neural Crest Cells Originating Conditions: Neuroblastoma and Congenital Heart Disease. <i>Genes</i> , 2019 , 10,	4.2	8	
8	HIF-1 transcription activity: HIF1A driven response in normoxia and in hypoxia. <i>BMC Medical Genetics</i> , 2019 , 20, 37	2.1	20	
7	BAP1 induces cell death via interaction with 14-3-3 in neuroblastoma. <i>Cell Death and Disease</i> , 2018 , 9, 458	9.8	21	
6	Somatic mutations in specific and connected subpathways are associated with short neuroblastoma patientsasurvival and indicate proteins targetable at onset of disease. <i>International Journal of Cancer</i> , 2018 , 143, 2525-2536	7.5	15	
5	FKBP51s signature in peripheral blood mononuclear cells of melanoma patients as a possible predictive factor for immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2017 , 66, 1143-1151	7.4	7	
4	An 18 gene expression-based score classifier predicts the clinical outcome in stage 4 neuroblastoma. <i>Journal of Translational Medicine</i> , 2016 , 14, 142	8.5	30	
3	Exome and deep sequencing of clinically aggressive neuroblastoma reveal somatic mutations that affect key pathways involved in cancer progression. <i>Oncotarget</i> , 2016 , 7, 21840-52	3.3	53	
2	A comprehensive characterization of rare mitochondrial DNA variants in neuroblastoma. <i>Oncotarget</i> , 2016 , 7, 49246-49258	3.3	8	
1	Genetic analysis of the novel SARS-CoV-2 host receptor TMPRSS2 in different populations		5	